Physician profile
Stephen Mark Fly
NPI 1588708911
$629.56
in general payments reported to CMS, 2019-2025
9 companies · $27.03 in 2025
The $27.03 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $152 · 2021: $63.95 · 2022: $64.89 · 2023: $142 · 2024: $40.29 · 2025: $27.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $209.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $186.29 | 2019-2025 | Clareon |
| Johnson & Johnson Surgical Vision, INC. | $113.76 | 2023 | Tecnis Simplicity |
| Carl Zeiss Meditec, INC. | $109.25 | 2019-2021 | |
| Rxsight INC | $74.76 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Carl Zeiss Meditec USA, INC. | $47.15 | 2022 | |
| Staar Surgical Company | $39.03 | 2019 | |
| Tearlab Corp | $28.20 | 2023 | Tearlab Osmolarity System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $18.97 | 2020 | |
| The Cameron-Ehlen Group, INC. | $12.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Fly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.